US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALPS Medical Breakthroughs ETF

56.15

-0.4900-0.87%

Post-market: 56.150.00000.00%19:30 EDT

Volume:59.46K

Turnover:3.36M

Market Cap:203.54M

PE:- -

High:57.37

Open:57.37

Low:55.93

Close:56.64

52wk High:70.85

52wk Low:39.40

Shares:3.63M

Float Shares:3.63M

Volume Ratio:1.87

T/O Rate:1.64%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Top Premarket Decliners

MT Newswires Live

U.S. Stocks on the MOVE-Netflix, Etsy, Viant Technology

Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword

Xenon Pharmaceuticals Inc. : Deutsche Bank Cuts to Hold from Buy; Cuts Target Price to $46 from $90

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)

Xenon Pharmaceuticals Shares Fall 27,5% Premarket After Co Pauses New Enrollment in Depression Drug Trials

THOMSON REUTERS

Xenon Pharmaceuticals Inc. : RBC Cuts Target Price to $70 from $81

THOMSON REUTERS

Stocks to Watch: Xenon Pharmaceuticals, Ultragenyx Pharmaceutical, BRT Apartments

CG Oncology Director Leonard E. Post Disposes of 1,000 Common Shares Worth $72,980

Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects

Xenon Submits FDA NDA for Azetukalner in Focal Seizures

Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies

THOMSON REUTERS

Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

THOMSON REUTERS

Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027

THOMSON REUTERS

Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies

THOMSON REUTERS

Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/SBIO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":56.15,"timestamp":1790971200000,"preClose":56.64,"halted":0,"volume":59461,"hourTrading":{"tag":"盘后","latestPrice":56.15,"preClose":56.15,"latestTime":"19:30 EDT","volume":75,"amount":4095.0633,"timestamp":1790983804718,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00865112994350286,"floatShares":3625000,"shares":3625000,"eps":0,"marketStatus":"Market Closed","change":-0.49,"latestTime":"10-02 16:00:00 EDT","open":57.37,"high":57.37,"low":55.925,"amount":3364430.983306,"amplitude":0.025512,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":56.64,"sharesOutstanding":2675000,"nav":56.22,"aum":198187245.53,"bidAskSpread":0.002427,"postHourTrading":{"tag":"盘后","latestPrice":56.15,"preClose":56.15,"latestTime":"19:30 EDT","volume":75,"amount":4095.0633,"timestamp":1790983804718,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.8675640977225254,"impliedVol":0.2697,"impliedVolPercentile":0.8486},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","floatShares":3625000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.8675640977225254,"shares":3625000,"dividePrice":0,"high":57.37,"amplitude":0.025512,"preClose":56.64,"low":55.925,"week52Low":39.4,"pbRate":"--","week52High":70.85,"institutionHeld":0,"latestPrice":56.15,"eps":0,"divideRate":0,"volume":59461,"delay":0,"ttmEps":0,"open":57.37,"prevYearClose":51.22,"prevWeekClose":57.56,"prevMonthClose":58.3,"prevQuarterClose":58.3,"fiveDayClose":57.56,"twentyDayClose":67.31,"sixtyDayClose":68.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBIO\",params:#limit:5,,,undefined,":[{"date":"2024-12-19","symbol":"SBIO","amount":1.17346,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-19","defaultRemindTime":1734618600000,"name":"ALPS Medical Breakthroughs ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-19","currency":"USD","dateTimestamp":1734584400000,"payDate":"2024-12-26"},{"date":"2023-12-21","symbol":"SBIO","amount":0.07106,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-22","defaultRemindTime":1703169000000,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2023-12-27","payableDate":"2023-12-22","currency":"USD","dateTimestamp":1703134800000,"payDate":"2023-12-27"},{"market":"US","date":"2019-12-19","symbol":"SBIO","amount":0.01585,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2019-12-27","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-20","symbol":"SBIO","amount":0.78406,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2018-12-27","payableDate":"2018-12-21","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBIO\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.78406,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":"2019-12-27","value":0.01585,"currency":"USD"},{"executeDate":"2023-12-21","recordDate":"2023-12-22","paymentDate":"2023-12-27","value":0.07106,"currency":"USD"},{"executeDate":"2024-12-19","recordDate":"2024-12-19","paymentDate":"2024-12-26","value":1.17346,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBIO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBIO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668928727","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2668928727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668928727?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:43","pubTimestamp":1789731804,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals  shares were down nearly 26% in premarket trading Friday after the company paused enrollment of new patients in studies for major depressive disorder and bipolar depression.Digital Currency X Technology  stock was more than 19% lower following a 38% rise in Thursday's session.ALX Oncology  stock was 8% lower, extending the 1% loss from Thursday's session.Stewards  shares were down 8%, partially reversing the 18% rise at the prior close.Hotel101 Global  stock was 7% lower following a 0.9% advance.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SBIO","BK4024","IBRN","ALXO","BK4099","HBNB","BK4139","XENE","SWRD","DCX","BK4164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668287309","title":"U.S. Stocks on the MOVE-Netflix, Etsy, Viant Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2668287309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668287309?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:41","pubTimestamp":1789731687,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Etsy, Viant TechnologyWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nL6N45A0PR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0127658192.USD","LU0942090050.USD","IE00B19Z3B42.SGD","BK4598","LU1223082519.USD","BK4585","GFI","BK4017","BK4588","IE00BQXX3D17.EUR","LU1429558221.USD","LU0055631609.USD","LU2362540622.SGD","LU2498475776.HKD","LU2108987350.USD","LU0143863198.USD","IE00B19Z9505.USD","GLDN","BK4532","LU2361044865.SGD","LU0203202063.USD","LU0654597011.USD","LU0320765059.SGD","LU1720051017.SGD","LU2326559502.SGD","LU0498741890.SGD","SGXZ51526630.SGD","LU0079474960.USD","LU1316542783.SGD","LU1046421795.USD","AU","LU0210533765.USD","LU1989764664.SGD","LU0225283273.USD","LU0498741114.HKD","LU1814569148.SGD","BK4144","LU1366192091.USD","PXI","LU0303823156.USD","IE00BZ1G4Q59.USD","IE00BQXX3F31.USD","LU0075056555.USD","TRUM","GXPC","LU0234570918.USD","FMTL","BK4566","BK4551","IE00BKDWB100.SGD","LU0368265418.SGD","LU0612318971.USD","BK4522","LU0788109121.HKD","LU1868838027.USD","LU2552382215.SGD","BK4122","NEMG","SGDM","NWMX","MLPI","LU2860962120.EUR","LU0122376428.USD","LU0719512351.SGD","LU0786609619.USD","BK4581","SG9999001143.SGD","LU0215105999.USD","NFLX","LU0266512473.USD","GDMN","UMI","LU1883866441.USD","LU0642271901.SGD","LU0300736492.USD","SGXZ23171101.USD","AGMI","LU0345780521.USD","XLC","LU0672654240.SGD","LU0256863811.USD","NEM","LU2237957902.USD","SGXZ81514606.USD","LU1223082196.USD","NFXL","SBIO","LU0353189680.USD","LU0456854461.SGD","IE00B1XK9C88.USD","LU0330918003.SGD","LU0082616367.USD","LU2543165471.USD","AFK","LU0077335932.USD","LU2461242641.AUD","NFLW","LU1435385759.SGD","LU0278409577.USD","LU0203201768.USD","LU1069344957.HKD","IE00BKVL7J92.USD","AUMI","LU1430597077.USD","LU0788108826.HKD","LU0198837287.USD","LU0882574139.USD","LU0612318385.USD","LU2462611646.USD","LU0234572021.USD","LU2361044949.HKD","LU0006306889.USD","LU0353189763.USD","BK4139","LU0170899867.USD","BK4534","LU1232071149.USD","GDX","LU0788109394.HKD","LU2896262040.SGD","BK4220","BK4548","MLPX","LU1720051108.HKD","BK4108","LU2362541273.HKD","IE00B19Z8W00.USD","LU0708995401.HKD","SNFLXmain","LU1267930730.SGD","LU1674673428.USD","LU0417517546.SGD","LU0106261372.USD","SGXZ99366536.SGD","IE00BQXX3C00.GBP","LU0868494617.USD","LU0496367417.USD","SLVP","BK4023","LU0368265764.SGD","LU0640476718.USD","BK4527","LU1868837565.USD","LU0300736062.USD","LU0345780950.USD","LU1201861249.SGD","NFLP","LU1064131342.USD","LU0109391861.USD","LU0477156953.USD","LU2237957811.SGD","LU2361045086.USD","LU1235294995.USD","LU1778281490.HKD","IE00BWXC8680.SGD","BK4524","LU0345780281.USD","LU1823568750.SGD","LU2362541513.USD","HMY","LU0256863902.USD","LU0724618789.USD","LU1127390331.HKD","XENE","AUAU","BK4533","LU1223083913.SGD","LU2087625088.SGD","LU1548497426.USD","LU0130102774.USD","LU0210536198.USD","LU1023059493.AUD","LU1674673691.USD","LU0054578231.USD","NFLU","FCOM","LU0868494708.USD","IE00B19Z8X17.USD","TRGP","IE00B19Z3581.USD","LU1035775433.USD","LU0097036916.USD","LU0143863784.USD","LU0266512127.USD","LU0345781412.USD","SG9999004303.SGD","LU0648001328.SGD","BK4507","IE00BKPKM429.USD","DSP","LU1102505762.USD","LU0303821028.USD","LU0980610538.SGD","NFXS","LU2264538146.SGD","LU2449327464.USD","BK4587","LU1988902786.USD","BK4570","TPZ","NFX","GOAU","LU1979441026.SGD","LU1102505929.USD","ETSY","LU2552382058.USD","LU2552382132.HKD","NFLY","LU0130517989.USD","IBRN","LU1280957306.USD","LU2357305700.SGD","IE0002270589.USD","LU0630314457.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668281179","title":"Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword","url":"https://stock-news.laohu8.com/highlight/detail?id=2668281179","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668281179?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:32","pubTimestamp":1789731120,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals said it submitted a regulatory filing for its lead drug candidate that puts it on the brink of its first commercial product. However, what should have been a celebratory moment f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","SBIO","DBB","XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668205940","title":"Xenon Pharmaceuticals Inc. : Deutsche Bank Cuts to Hold from Buy; Cuts Target Price to $46 from $90","url":"https://stock-news.laohu8.com/highlight/detail?id=2668205940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668205940?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:08","pubTimestamp":1789729727,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","BK4139","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668940452","title":"Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940452?lang=en_us&edition=fundamental","pubTime":"2026-09-18 18:50","pubTimestamp":1789728612,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB) w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neuronetics-stim-xenon-xene-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neuronetics-stim-xenon-xene-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","IE00B894F039.SGD","BK4585","XBI","BIIB","XENE","BK4581","BMED","LU0234570918.USD","BK4533","STIM","SBIO","LABU","IE00B19Z9Z06.USD","BK4588","IBRN","LU0889565916.HKD","XLV","BK4082","LU0320765992.SGD","LU0128526141.USD","PBE","IE00B19Z9P08.USD","LU0029874061.USD","LU0109394709.USD","HCSG","BK4137","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668619946","title":"Xenon Pharmaceuticals Shares Fall 27,5% Premarket After Co Pauses New Enrollment in Depression Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2668619946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668619946?lang=en_us&edition=fundamental","pubTime":"2026-09-18 16:05","pubTimestamp":1789718717,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nL4N45A0OY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668124829","title":"Xenon Pharmaceuticals Inc. : RBC Cuts Target Price to $70 from $81","url":"https://stock-news.laohu8.com/highlight/detail?id=2668124829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668124829?lang=en_us&edition=fundamental","pubTime":"2026-09-18 12:30","pubTimestamp":1789705824,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN4590QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668990047","title":"Stocks to Watch: Xenon Pharmaceuticals, Ultragenyx Pharmaceutical, BRT Apartments","url":"https://stock-news.laohu8.com/highlight/detail?id=2668990047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668990047?lang=en_us&edition=fundamental","pubTime":"2026-09-18 07:08","pubTimestamp":1789686480,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals said adverse events in trials of azetukalner to treat depression and bipolar disorder led it to pause enrollment voluntarily. Shares tumbled 26%, to $42.35, after Thursday's bell.Ultragenyx Pharmaceutical's Fayuvi drug received Food and Drug Administration approval to treat children with Sanfilippo syndrome type A. The stock closed up 13%, at $14.50, and gained another 1.7% after the bell.BRT Apartments said its board approved a $10 million replenishment for its stock-buyback program. Shares rose 2.9%, to $14.22, after-hours.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","IBRN","BK4215","XENE","BK4139","SBIO","BRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668992677","title":"CG Oncology Director Leonard E. Post Disposes of 1,000 Common Shares Worth $72,980","url":"https://stock-news.laohu8.com/highlight/detail?id=2668992677","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668992677?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:31","pubTimestamp":1789677113,"startTime":"0","endTime":"0","summary":"CG Oncology director Leonard E. Post disposes of 1,000 common shares worth $72,980CG Oncology director Leonard E. Post sold 1,000 shares on Sep. 15, 2026 at USD 72.98.He also exercised director stock ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL2LTwlF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CG Oncology Director Leonard E. Post Disposes of 1,000 Common Shares Worth $72,980","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON","LU2324357040.USD","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668501992","title":"Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2668501992","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668501992?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:27","pubTimestamp":1789676867,"startTime":"0","endTime":"0","summary":"BUZZ-Xenon Pharma plunges after pausing trial enrollment due to side effects** Shares of Xenon PharmaceuticalsXENE.Oslides 21.59% to $44.97 in extended trading** Xenon says it pauses enrollment of new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4N4591PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","SBIO","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668947909","title":"Xenon Submits FDA NDA for Azetukalner in Focal Seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2668947909","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668947909?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675304,"startTime":"0","endTime":"0","summary":"Xenon submits FDA NDA for azetukalner in focal seizuresXenon submitted an FDA New Drug Application for azetukalner to treat focal seizures.Filing supported by positive Phase 2b X-TOLE and Phase 3 X-TO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL6fvsBp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","IE00BQXX3D17.EUR","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","LU2210150020.SGD","XENE","SBIO","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","IBRN","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","BK4588","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994767","title":"Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994767?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","SBIO","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994765","title":"Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994765?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","XENE","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994750","title":"Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994750?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","BK4139","IBRN","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994710","title":"Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994710?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","XENE","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666590103","title":"Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590103","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666590103?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:14","pubTimestamp":1789064040,"startTime":"0","endTime":"0","summary":"Biohaven has hit another regulatory hurdle for its epilepsy candidate opakalim, piling fresh uncertainty onto the cash-strapped biotech.Biohaven confirmed Thursday that the Food and Drug Administratio","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","XENE","BK4139","LU1093756168.USD","BHVN","IBRN","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FXH","WDNA","JDOC","SBIO","BBH","GSKH","NVIB","MNTL","AZNH","LFSC","HRTS","GNOM","LLYX","IBRN","MEDI","PBPH","GNMX","MDTX","BBP","IBB","MEDX","GDOC","GPCR","PJP","BME","BIB","CANC","FBT","CURE","FHLC","TBXU","IBBQ","PTH","IEIH","IDNA","RSPH","XPH","JHMH","FTXH","CNCR","APXH","PSCH","IBBJ","SURI","PINK","SYNB","HYLG","PBE","PSIL","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BME","BBP","AZNH","JDOC","GNOM","MRNY","CNCR","FHLC","PBPH","LFSC","RSPH","WDNA","GDOC","PJP","BIB","CANC","GNMX","GSKH","IBRN","SURI","PSIL","TBXU","CURE","FXH","PINK","SBIO","FTXH","SYNB","LENZ","IBB","PTH","NVIB","APXH","BBH","MEDI","HYLG","HRTS","JHMH","MNTL","GPCR","FBT","MDTX","PBE","IBBQ","PSCH","XPH","IBBJ","LLYX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127014248","title":"AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=1127014248","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127014248?lang=en_us&edition=fundamental","pubTime":"2026-09-04 09:44","pubTimestamp":1788486257,"startTime":"0","endTime":"0","summary":"AbbVie (NYSE: ABBV) announced on Thursday that it has finalized its $10.9 billion acquisition of inflammation drug developer Apogee Therapeutics (NASDAQ: APGE). This transaction marks the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LU2468319806.SGD","SG9999015986.USD","LU0708994859.HKD","LU0234570918.USD","LU1929549753.HKD","BK4559","IXJ","AGNG","LU0211328371.USD","LU1585245621.USD","IE000MB6IJN5.SGD","SG9999015945.SGD","LU0320765646.SGD","SG9999015952.SGD","LU1057294990.SGD","LU0553294199.USD","LU0289961442.SGD","BK4550","LU1496350502.SGD","LU2112291526.USD","LU1037948897.HKD","LU2125909593.SGD","LU0256863811.USD","LU2347655073.USD","LU1093756168.USD","BK4581","LU1934455863.HKD","LU0661504455.SGD","LU0395794307.EUR","XMMO","LU0058720904.USD","LU0029864427.USD","LU0456855351.SGD","LU0256863902.USD","IE0002270589.USD","IE0009355771.USD","IE00B42XCP33.USD","LU2237443465.HKD","LU2433249047.HKD","LU2237443382.USD","LU2237443978.SGD","IE000WAW04H5.SGD","LU1934455277.USD","IE00BBT3K403.USD","LU0098860793.USD","LU2129689514.USD","LU0795875169.SGD","LU1244550577.SGD","LU1923622614.USD","LU0289739699.SGD","LU1934455194.USD","LU0158827948.USD","XLV","PPH","LU1267930490.SGD","LU0912757837.SGD","LU0289739343.SGD","LU0726765562.USD","IE000F7OJYX1.SGD","LU0198837287.USD","LU2129689431.USD","LU1003077747.HKD","LU1551013425.SGD","IE00BVYPNV92.GBP","LU0738911758.USD","LU0942090050.USD","IE00BN8TJ469.HKD","IE00B4R5TH58.HKD","LU0965509101.SGD","IE00BJJMRZ35.SGD","LU0859254822.USD","LU2089284900.SGD","LU2357627491.SGD","RXL","LU0965509010.AUD","LU0069063385.USD","BK4139","LU0057025933.USD","MYLD","LU2133065610.SGD","BK4533","LU0053671581.USD","MEDX","LU1430594728.SGD","LU2089283258.USD","SG9999011175.SGD","LU2129689605.HKD","IE0000B7K699.USD","LU0985320562.USD","LU1670627923.USD","IE00BLSP4452.SGD","BK4566","IE00BLSP4239.USD","LU0114720955.EUR","LU0861579265.USD","IE00BFTCPJ56.SGD","LU0124676726.USD","LU1291159041.SGD","LU2023251221.USD","LU1718418525.SGD","LU1023059063.AUD","LU0795875086.SGD","LU1732799900.SGD","LU1989771016.USD","LU0965509283.SGD","SG9999015978.USD","LU1236620834.HKD","LU0689626769.HKD","IE00B19Z3B42.SGD","LU1839511570.USD","LU0128525929.USD","LU1983299246.USD","IE00BGHQF631.EUR","LU0170899867.USD","LU0203347892.USD","LU0868494708.USD","IYH","LU0122379950.USD","LU0545039389.USD","LU1267930573.SGD","LU0949170772.SGD","CALF","LU1496350171.SGD","LU0310800379.SGD","LU2347655156.SGD","LU1732800096.USD","LU1244550221.USD","LU0234572021.USD","LU0211327993.USD","ABBV","IE00BJT1NW94.SGD","LU0203345920.USD","SG9999003800.SGD","LU2237443622.USD","LU1162221912.USD","GLAM","LU1061106388.HKD","BK4588","SG9999001440.SGD","IE00BDGV0183.EUR","PJP","LU0823416689.USD","IE000BZT7R73.USD","TRUH","LU0820561818.USD","LU1244550494.USD","LU0432979614.USD","BK4585","KCE","LU2237443895.HKD","JDOC","BK4534","LU1989772923.USD","FTXH","IE00B19Z3581.USD","VHT","LU1236620750.USD","LU1989772840.SGD","SBIO","LU2125909247.SGD","IE0004445239.USD","IE000SO60NU8.SGD","LU0417517546.SGD","IE0002141913.USD","APGE","LU2237443549.SGD","IE00BVYPNW00.USD","LU0820561909.HKD","LU0472753341.HKD","IE00B2B36J28.USD","LU0689472784.USD","LU0868494617.USD","LU1670628061.USD","LU1093756325.SGD","LU1037948541.HKD","LU0511384066.AUD","LU2089984988.USD","LU0310799852.SGD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","LU1551013342.USD","LU1074936037.SGD","LU2087621335.USD","LU0943347566.SGD","LU0882574055.USD","LU0965508806.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664080500","title":"Sector Update: Healthcare Stocks Higher Thursday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2664080500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664080500?lang=en_us&edition=fundamental","pubTime":"2026-09-04 01:49","pubTimestamp":1788457760,"startTime":"0","endTime":"0","summary":"Healthcare stocks were slightly higher Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF  up 0.1%.The iShares Biotechnology ETF  eased 0.3%.In corporate news, Hutchmed  shares jumped 17% after the company said its unit licensed rights to GSK  to develop and commercialize experimental cancer treatment HMPL-A830 outside greater China. GSK shares added 0.8%.AbbVie  said Thursday that it has completed its acquisition of Apogee Therapeutics , valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share. AbbVie shares were down 0.3%.Ultragenyx Pharmaceutical  shares fell 45% after the firm said a phase 3 study of apazunersen in Angelman syndrome did not achieve the primary endpoint nor a key secondary endpoint.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1244550577.SGD","LU0124676726.USD","RXL","IE00BGHQF631.EUR","TRUH","LU0820561909.HKD","LU0289961442.SGD","GSK.UK","XBI","HCM","GLAM","LU0432979614.USD","LU0708994859.HKD","LU2237443382.USD","IXJ","GSKH","LU0256863811.USD","LU0553294199.USD","SBIO","LABU","AGNG","APGE","FTXH","LU1989772923.USD","BK4534","LU1718418525.SGD","FHLC","XLV","PJP","LU0203345920.USD","IYH","JDOC","VHT","RARE","IE00BJJMRZ35.SGD","PPH","GSK","LU0029864427.USD","LU0114720955.EUR","LU0128525929.USD","ABBV","LU1236620750.USD","LU2125909593.SGD","HCSG","BK4137","MEDX","LU1496350171.SGD","IE0004445239.USD","IE00B4R5TH58.HKD","IBB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":121,"code":"91000000","status":"200"}]}}